Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PTEN mutant |
Therapy | GSK2256098 + Paclitaxel |
Indication/Tumor Type | uterine cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN mutant | uterine cancer | sensitive | GSK2256098 + Paclitaxel | Preclinical | Actionable | In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Taxol (paclitaxel) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835). | 25833835 |
PubMed Id | Reference Title | Details |
---|---|---|
(25833835) | PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. | Full reference... |